SNSS Share Price

Open 3.93 Change Price %
High 4.07 1 Day 0.12 3.08
Low 3.93 1 Week -0.07 -1.71
Close 4.02 1 Month 0.28 7.49
Volume 23015 1 Year 3.16 367.44
52 Week High 5.00
52 Week Low 0.44
SNSS Important Levels
Resistance 2 4.15
Resistance 1 4.10
Pivot 4.01
Support 1 3.94
Support 2 3.89
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SIRI 4.33 0.70%
SUSQ 14.20 -0.77%
AAPL 109.10 -0.73%
AAPL 109.10 -0.73%
More..
NASDAQ USA Top Gainers Stocks
QKLS 0.21 110.00%
LLEN 0.03 50.00%
LOCM 0.09 50.00%
RITT 0.09 50.00%
MEMP 0.64 33.33%
SKBI 0.19 26.67%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
CLNT 0.88 23.94%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
LIWA 0.01 -50.00%
AMCF 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS)

SNSS Technical Analysis 2
As on 5th Dec 2016 SNSS Share Price closed @ 4.02 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 1.58 & Sell for SHORT-TERM with Stoploss of 4.14 we also expect STOCK to react on Following IMPORTANT LEVELS.
SNSS Target for December
1st Target up-side 4.4
2nd Target up-side 4.68
3rd Target up-side 4.96
1st Target down-side 3.6
2nd Target down-side 3.32
3rd Target down-side 3.04
SNSS Other Details
Segment EQ
Market Capital 190775152.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.sunesis.com
SNSS Address
SNSS
395 Oyster Point Boulevard
Suite 400
South San Francisco, CA 94080
United States
Phone: 650-266-3500
Fax: 650-266-3501
Interactive Technical Analysis Chart Sunesis Pharmaceuticals, Inc. ( SNSS NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Sunesis Pharmaceuticals, Inc.
SNSS Business Profile
Sunesis Pharmaceuticals, Inc. (Sunesis) is a biopharmaceutical company focused on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The Company is focuses primarily on the development of vosaroxin for the treatment of acute myeloid leukemia (AML). Vosaroxin is a anti-cancer quinolone derivative (AQD). AQDs have been shown to mediate anti-tumor activity by targeting mammalian topoisomerase II, an enzyme critical for cell replication. The Company owns worldwide development and commercialization rights to vosaroxin. The Company�s VALOR trial is designed to evaluate the effect of vosaroxin in combination with cytarabine, chemotherapy in AML. The trial has an adaptive design and is based on data from the Company's Phase II clinical trial of vosaroxin in combination with cytarabine in relapsed or refractory AML.